SB 375 – This act requires health insurance companies to provide coverage for routine patient care costs incurred as the result of phase I clinical trials undertaken to treat cancer. Currently, Section 376.429, RSMo, requires coverage for phases II, III, or IV only. This act also removes any of the additional prerequisites for coverage for phase II trials that do not apply to phase III of IV trials.

This act is identical to HB 886 (2009).


Return to Main Bill Page